Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer

Circulating Biomarkers of CDK4/6 Inhibitors Response in Hormone Receptor Positive and HER2 Negative Breast Cancer

CDK4/6 inhibitors (CDK4/6i) and endocrine therapy are the standard treatment for patients with hormone receptor-positive and HER2 negative (HR+/HER2−) metastatic breast cancer. Patients might show intrinsic and acquired resistance, which leads to treatment failure and progression. Circulating biomar...

Full description

Bibliographic Details
Main Authors: Ilenia Migliaccio, Angela Leo, Francesca Galardi, Cristina Guarducci, Giulio Maria Fusco, Matteo Benelli, Angelo Di Leo, Laura Biganzoli, Luca Malorni
Format: Article
Language:English
Published: MDPI AG 2021-05-01
Series:Cancers
Subjects:
CDK4/6 inhibitors
circulating biomarkers
liquid biopsy
therapy resistance
breast cancer
Online Access:https://www.mdpi.com/2072-6694/13/11/2640

Internet

https://www.mdpi.com/2072-6694/13/11/2640

Similar Items